Treffer: Adverse events of trabecular micro-bypass minimally invasive glaucoma surgery devices: a five-year analysis from the FDA MAUDE database.
Original Publication: The Hague, Junk.
Allison K, Patel D, Alabi O (2020) Epidemiology of glaucoma: the past, present, and predictions for the future. Cureus 12(11):e11686. https://doi.org/10.7759/cureus.11686. (PMID: 10.7759/cureus.11686333919217769798)
Tham Y-C, Li X, Wong TY, Quigley HA, Aung T, Cheng C-Y (2014) Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. Ophthalmology 121(11):2081–2090. https://doi.org/10.1016/j.ophtha.2014.05.013. (PMID: 10.1016/j.ophtha.2014.05.01324974815)
Dubey S, Drishti C (2024) Minimally invasive glaucoma surgery: a comprehensive review. GJCSRO 3:92–101. https://doi.org/10.25259/GJCSRO_34_2024. (PMID: 10.25259/GJCSRO_34_2024)
Manasses DT, Au L (2016) The new era of glaucoma micro-stent surgery. Ophthalmol Ther 5(2):135–146. https://doi.org/10.1007/s40123-016-0054-6. (PMID: 10.1007/s40123-016-0054-6273142345125116)
SooHoo JR, Seibold LK, Radcliffe NM, Kahook MY (2014) Minimally invasive glaucoma surgery: current implants and future innovations. Can J Ophthalmol 49(6):528–533. https://doi.org/10.1016/j.jcjo.2014.09.002. (PMID: 10.1016/j.jcjo.2014.09.00225433743)
Ahmed IIK, De Francesco T, Rhee D et al (2022) Long-term outcomes from the HORIZON randomized trial for a Schlemm’s canal microstent in combination cataract and glaucoma surgery. Ophthalmology 129(7):742–751. https://doi.org/10.1016/j.ophtha.2022.02.021. (PMID: 10.1016/j.ophtha.2022.02.02135218867)
Samuelson TW, Sarkisian SR, Lubeck DM et al (2019) Prospective, randomized, controlled pivotal trial of an ab interno implanted trabecular micro-bypass in primary open-angle glaucoma and cataract: two-year results. Ophthalmology 126(6):811–821. https://doi.org/10.1016/j.ophtha.2019.03.006. (PMID: 10.1016/j.ophtha.2019.03.00630880108)
Bidiwala S, Jabarkhyl D, Bidiwala K (2025) Outcomes of minimally invasive glaucoma surgery (MIGS) in glaucoma patients with coexisting cataract: a systematic review and meta-analysis. Cureus 17(1):e77007. https://doi.org/10.7759/cureus.77007. (PMID: 10.7759/cureus.770073991203211798616)
Balas M, Mathew DJ (2023) Minimally invasive glaucoma surgery: a review of the literature. Vision (Basel). https://doi.org/10.3390/vision7030054. (PMID: 10.3390/vision703005437606500)
Duong AT, Yuan M, Koenig LR, Rodriguez GH, Van Tassel SH (2021) Adverse events associated with microinvasive glaucoma surgery reported to the Food and Drug Administration. Ophthalmol Glaucoma 4(4):433–435. https://doi.org/10.1016/j.ogla.2020.12.012. (PMID: 10.1016/j.ogla.2020.12.01233421640)
Samuelson TW, Chang DF, Marquis R et al (2019) A Schlemm canal microstent for intraocular pressure reduction in primary open-angle glaucoma and cataract: the HORIZON study. Ophthalmology 126(1):29–37. https://doi.org/10.1016/j.ophtha.2018.05.012. (PMID: 10.1016/j.ophtha.2018.05.01229945799)
Ahmed IIK, Fea A, Au L et al (2020) A prospective randomized trial comparing Hydrus and iStent microinvasive glaucoma surgery implants for standalone treatment of open-angle glaucoma: the COMPARE study. Ophthalmology 127(1):52–61. (PMID: 10.1016/j.ophtha.2019.04.03431034856)
James JE (2017) Reviving Cochrane’s contribution to evidence-based medicine: bridging the gap between evidence of efficacy and evidence of effectiveness and cost-effectiveness. Eur J Clin Invest 47(9):617–621. https://doi.org/10.1111/eci.12782. (PMID: 10.1111/eci.1278228675422)
Capitena Young CE, Ammar DA, Seibold LK, Pantcheva MB, SooHoo JR, Kahook MY (2018) Histopathologic examination of trabecular meshwork changes after trabecular bypass stent implantation. J Glaucoma 27(7):606–609. https://doi.org/10.1097/IJG.0000000000000968. (PMID: 10.1097/IJG.000000000000096829965891)
Doshi RR, Arevalo JF, Flynn HW, Cunningham ET (2010) Evaluating exaggerated, prolonged, or delayed postoperative intraocular inflammation. Am J Ophthalmol 150(3):295-304.e1. https://doi.org/10.1016/j.ajo.2010.04.012. (PMID: 10.1016/j.ajo.2010.04.01220630493)
Anderson JM, Rodriguez A, Chang DT (2008) Foreign body reaction to biomaterials. Semin Immunol 20(2):86–100. https://doi.org/10.1016/j.smim.2007.11.004. (PMID: 10.1016/j.smim.2007.11.00418162407)
Hydrus® Microstent Instructions for Use. https://www.accessdata.fda.gov/cdrh_docs/pdf17/P170034D.pdf. Accessed August 19, 2025.
Le K, Saheb H (2014) IStent trabecular micro-bypass stent for open-angle glaucoma. Clin Ophthalmol 8:1937–1945. https://doi.org/10.2147/OPTH.S45920. (PMID: 10.2147/OPTH.S45920252849804181749)
Chansangpetch S, Ittarat M, Yang S, Fisher AC, Singh K, Lin SC, Chang RT (2020) Comparison of 1-year effectiveness of trabecular microbypass stent implantation (iStent) in conjunction with phacoemulsification among mild, moderate, and severe primary open-angle glaucoma patients. J Glaucoma 29(7):542–549. https://doi.org/10.1097/IJG.0000000000001542. (PMID: 10.1097/IJG.000000000000154232433095)
About Manufacturer and User Facility Device Experience (MAUDE) Database | FDA. https://www.fda.gov/medical-devices/mandatory-reporting-requirements-manufacturers-importers-and-device-user-facilities/about-manufacturer-and-user-facility-device-experience-maude-database. Accessed June 3, 2025.
Muijzer MB, Schellekens PAWJ, Beckers HJM, de Boer JH, Imhof SM, Wisse RPL (2022) Clinical applications for intraoperative optical coherence tomography: a systematic review. Eye 36(2):379–391. https://doi.org/10.1038/s41433-021-01686-9. (PMID: 10.1038/s41433-021-01686-934272509)
Weitere Informationen
Background: In 2020, 76 million people around the world had glaucoma, and by 2040, that number is predicted to rise to 111.8 million. Minimally invasive glaucoma surgery (MIGS) has become an effective method to treat open-angle glaucoma. It lowers the pressure inside the eye by improving the drainage mechanism of the eye's aqueous humor. MIGS devices, such as the iStent® and Hydrus®, aid in aqueous outflow and patency maintenance. However, their long-term safety and efficacy require ongoing post-market surveillance across diverse patient populations. It's important to know how safe implanted devices like MIGS are over a long period of time.
Objective: To conduct a five-year retrospective analysis of adverse events associated with the Hydrus® Microstent and iStent® trabecular micro-bypass MIGS devices, as reported in the U.S. Food and Drug Administration (FDA)'s Manufacturer and User Facility Device Experience (MAUDE) database, and to characterize the spectrum and reporting patterns of device- and patient-related complications to better define their real-world safety profile in glaucoma management.
Study Design: A retrospective case-series.
Methods: All MAUDE reports submitted between January 1, 2020, and October 31, 2024, containing product codes "OGO" and "KYF" were screened. A total of 784 eligible reports involving Hydrus and various iStent models were analyzed for device-related and patient-related adverse events. Descriptive statistics were used to summarize event types and frequencies. Heatmaps and visualizations were also created using Python Google Colab.
Results: Among 784 reports, injuries accounted for 63.1% of cases, and malfunctions for 36.9%. A total of 503 device-related and 1,012 patient-related problems were identified. Among device-related problems, malposition was the most commonly reported issue (37.3% of device problem reports), followed by breakage (23.5%) and obstruction (9.0%). Frequent patient-related events included increased IOP (19.4%), hyphema (12.1%), and foreign body in patients (10.6%). Among Hydrus®-related reports, malposition was the most frequently reported device issue; among iStent® Inject W reports, breakage predominated.
Conclusion: The Hydrus® and iStent® trabecular micro-bypass MIGS devices have shown generally favorable safety over five years of postmarket surveillance. However, device malposition and mechanical failures were frequently reported in voluntary submissions, though, due to the absence of denominator data, these reports cannot be interpreted as evidence of higher real-world incidence compared to clinical trials. These findings inform surgical training, patient counseling, and highlight the need for prospective real-world registries to establish true complication rates.
(© 2025. The Author(s), under exclusive licence to Springer Nature B.V.)
Declarations. Conflict of interest: The authors declare no competing interests.